کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2140036 | 1087924 | 2007 | 4 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
We have demonstrated that 12-0-tetradecanoylphorbol-13-acetate (TPA) combined with vitamin D3 (VD3) and cytosine arabinoside (Ara C) is effective and feasible for chronic myelogenous leukemia (CML) in blastic phase (BP). In the current study, the efficacy of TPA combined with inhibitor imatinib mesylate (imatinib) was investigated in patients with CML in BP that was resistant to standard-dose imatinib (400 mg/day). The results suggested that TPA combined with imatinib (400 mg/day) might overcome disease-poor response to conventional doses. So this approach deserves further evaluation as frontline therapy for newly diagnosed CML.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 31, Issue 10, October 2007, Pages 1441–1444
Journal: Leukemia Research - Volume 31, Issue 10, October 2007, Pages 1441–1444
نویسندگان
Baijun Fang, Yongping Song, Zhengtao Han, Xudong Wei, Quande Lin, Xiaoxiu Zhu, Ruyu Yang, Junzhong Sun, Guofeng Tian, Xinjian Liu, Guoshun Cao, Yin Shi, Neng Nie, Dapeng Li, Robert Chunhua Zhao,